NLY01, a GLP-1R agonist developed based on exendin-4, has exhibited the remarkable ability to selectively inhibit microglia activation triggered by β-amyloid (Aβ) via GLP-1R activation in AD models [138]. This evidence concerns the gene GLP1R and Alzheimer disease.